My late friend, mentor and former UCL professor of medicine James Malone-Lee advised that a good clinician does the right things very well for patients, but a medical academic is charged to determine, through research, what the right things are to do. We both sought to determine the “right way” to treat bladder infections because he, as a geriatrician, and I, as a neurorehabilitation doctor treating people with CNS diseases such as #MS, saw so many routinely. James believed

The case for widening the #intravesical approach to #bladder diseases and disorders In the European Association of #Urology 2024 conference, intravesical chemotherapy “took centre stage:” https://www.linkedin.com/pulse/eau24-expert-commentary-professor-fufu-zheng-nmibc-postoperative-i6xre?trk=organization_guest_main-feed-card_feed-article-content The case for their use in uro-oncology was made over 60 years ago with the introduction of Mitiomycin C. The value in delivering d

UroPharma produced #intravesical drug-delivery technology to bring, under licence, better cystitis (lower #UTI) treatments. For decades,...

For some reason, we long assumed that #bacteria in the extra-systemic, #urinary cavity are subject to the same conditions as in other tissue infections, but they aren’t. #Antibiotics get to other tissue infections via blood whereas #cystitis #pathogens encounter antibiotics in #urine. That’s a big difference, first of all, blood pH range is narrow, so an antibiotic’s MIC (minimum inhibitory concentration) is predictable there. The urinary pH range is very wide. Antibiotic MIC